Diagnostic markers of chronic hepatitis B infection and disease

Antiviral Therapy

Volumn 15, Issue SUPPL. 3, 2010, Pages 35-44

  Bonino, Ferruccio ^a   Piratvisuth, Teerha ^b   Brunetto, Maurizia R ^c   Liaw, Yun Fan ^d  

^a UNIVERSITY OF PISA   (Italy)

^b PRINCE OF SONGKLA UNIVERSITY   (Thailand)

^c UNIVERSITY HOSPITAL OF PISA   (Italy)

^d CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA 2 MACROGLOBULIN; APOLIPOPROTEIN A1; BILIRUBIN; BIOLOGICAL MARKER; GAMMA GLUTAMYLTRANSFERASE; HAPTOGLOBIN; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; IMMUNOGLOBULIN M ANTIBODY; NUCLEIC ACID; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS DNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ANTIGEN DETECTION; ANTIVIRAL THERAPY; ASIA; BILIRUBIN BLOOD LEVEL; CANCER RISK; CENTRAL AFRICA; CENTRAL AMERICA; DIAGNOSTIC ACCURACY; DISEASE MARKER; EUROPE; FRANCE; GENOTYPE; GEOGRAPHIC DISTRIBUTION; GERMANY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; IN SITU HYBRIDIZATION; LIPOPROTEIN BLOOD LEVEL; LIVER BIOPSY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; MEXICO; MOLECULAR BIOLOGY; NON INVASIVE MEASUREMENT; NONHUMAN; NORTH AMERICA; NUCLEIC ACID ANALYSIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; SENSITIVITY AND SPECIFICITY; SOUTH AFRICA; SOUTH AMERICA; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; UNITED STATES; VIRUS DETECTION; VIRUS DIAGNOSIS; VIRUS GENOME; VIRUS LOAD; VIRUS REACTIVATION; VIRUS REPLICATION; VIRUS TYPING;

ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LIVER;

EID: 77957338379     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1622     Document Type: Review

References (106)

1. Blumberg BS, Alter HJ, Visnich SA. A 'new' antigen in leukemia sera. JAMA 1965; 196:541-546.
2. Stibbe W, Gerlich WH. Variable protein composition of hepatitis B surface antigen from different donors. Virology 1982; 123:436-442.
3. Nguyen T, Thompson AJV, Bowden S, et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol 2010; 52:508-513.
4. Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45:507-539.
5. Rotman Y, Brown AT, Hoofnagle JH. Evaluation of the patient with Hepatitis B. Hepatology 2009; 49 Suppl 5:S22-S27.
6. Hadziyannis SJ, Papatheodoridis GV. Hepatitis B e antigen-negative chronic hepatitis: natural history and treatment. Semin Liver Dis 2006; 26:130-141.
7. Raimondo G, Allain JP, Brunetto MR, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008; 49:652-657.
8. Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev 2000; 64:51-68.
9. Bonino F, Hoyer B, Nelson J, Engle R, Verme G, Gerin J. Hepatitis B virus DNA in the sera of HBsAg carriers: a marker of active hepatitis B virus replication in the liver. Hepatology 1981; 1:386-391.
10. Bonino F. The importance of hepatitis B viral DNA in serum and liver. J Hepatol 1986; 3:136-141.
11. Bonino F, Rosina F, Rizzetto M, et al. Chronic hepatitis in HBsAg carriers with serum HBV DNA and anti-HBe. Gastroenterology 1986; 90:1268-1273.
12. Chen CJ, Yang H, Iloeje UH, Reveal-HBV Study Group. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology 2009; 49 Suppl 5:S72-S84.
13. Hui CK, Leung N, Yuen ST, et al. Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase. Hepatology 2007; 46:395-401. (Pubitemid 47344774)
14. Papatheodoridis GV, Manesis EK, Manolakopoulos S, et al. Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection? Hepatology 2008; 48:1451-1459.
15. Okada K, Kamiyama I, Inomata M, et al. e Antigen and anti-e in the serum of asymptomatic carrier mothers as indicators of positive and negative transmission of hepatitis B virus to their infants. N Engl J Med 1976; 294:746-749.
16. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009; 373:582-592.
17. Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347:168-174.
18. Yu MW, Yeh SH, Chen PJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst 2005; 97:265-272.
19. Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130:678-686.
20. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295:65-67.
21. Chu CM, Hung SJ, Lin J, et al. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med 2004; 116:829-834.
22. Lin SM, Yu ML, Lee CM, et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 2007; 46:45-52.
23. Liaw YF, Yang SS, Chen TJ, et al. Acute exacerbation in hepatitis B e antigen positive chronic type B hepatitis. A clinicopathological study. J Hepatol 1985; 1:227-233.
24. Yang PM, Chen DS, Lai MY, et al. Clinicopathologic studies of asymptomatic HBsAg carriers: with special emphasis on carriers older than 40 years. Hepatogastroenterology 1987; 34:251-254.
25. Chu CM, Liaw YF. Predictive factors for reactivation of hepatitis B following hepatitis B e antigen seroconversion in chronic hepatitis B. Gastroenterology 2007; 133:1458-1465.
26. Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988; 8:493-496.
27. Hsu YS, Chien RN, Yeh CT, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002; 35:1522-1527.
28. Chu CM, Liaw YF. Chronic hepatitis B virus infection acquired in childhood: special emphasis on prognostic and therapeutic implication of delayed HBeAg seroconversion. J Viral Hepat 2007; 14:147-152.
29. Niederau C, Heintges T, Lange S, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996; 334:1422-1427.
30. Lin SM, Sheen IS, Chien RN, et al. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999; 29:971-975.
31. Fried MW, Piratvisuth T, Lau GKK, et al. HBeAg and Hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 2008; 47:428-434.
32. Budkowska A, Dubreuil P, Gerlich WH, et al. Occurrence of pre-S1 antigen in viremic and nonviremic carriers of hepatitis B surface antigen. J Med Virol 1988; 26:217-225.
33. Jaroszewicz J, Serrano BC, Wursthorn K, et al. Hepatitis B surface antigen (HBsAg) levels during the natural history of chronic hepatitis B: a European perspective. J Hepatol 2010; 52:514-522.
34. Brunetto MR, Oliveri F, Coco B, et al. Outcome of anti-HBe positive chronic hepatitis in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 2002; 36:263-270.
35. Bonino F, Brunetto MR. Chronic hepatitis B e antigen (HBeAg) negative, anti-HBe positive hepatitis B: an overview. J Hepatol 2003; 39 Suppl 1:S160-S163.
36. Brunetto MR, Oliveri F, Colombatto P, et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology 2010; 139:483-490.
37. Marzano A, Angelucci E, Andreone P, et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis 2007; 39:397-408.
38. Okamoto H, Tsuda F, Sakugawa H, et al. Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes. J Gen Virol 1988; 69:2575-2583.
39. Norder H, Courouce AM, Magnius LO. Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes. Virology 1994; 198:489-503.
40. Norder H, Courouce AM, Coursaget P, et al. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology 2004; 47:289-309.
41. Yuen M-F, Sablon E, Tanaka Y, et al. Epidemiological study of hepatitis B virus genotypes, core promoter and precore mutations of chronic hepatitis B infection in Hong Kong. J Hepatol 2004; 41:119-125. (Pubitemid 39005162)
42. Stuyver L, De Gendt S, Van Geyt C, et al. A new genotype of hepatitis virus: complete genome and phylogenetic relatedness. J Gen Virol 2000; 81:67-74.
43. Arauz-Ruiz P, Norder H, Robertson BH, et al. Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America. J Gen Virol 2002; 83:2059-2073.
44. Senturker Guldas N, Abacioglu YH. S-gene sequences and genotype-related restriction sites in hepatitis B virus carriers in Turkey. Infection 2004; 32:344-349.
45. Yalcin K, Degertekin H, Bahcecioglu IH, et al. Hepatitis B virus prevails in patients with persistently elevated or normal ALT levels in Turkey. Infection 2004; 32:24-29.
46. Suzuki Y, Kobayashi M, Ikeda K, et al. Persistence of acute infection with hepatitis B virus genotype A and treatment in Japan. J Med Virol 2005; 76:33-39.
47. Mayerat C, Mantegani A, Frei PC. Does hepatitis B virus (HBV) genotype influence the clinical outcome of HBV infection? J Viral Hepat 1999; 6:299-304.
48. Heijtink RA, Paulij W, van Roosmalen M, et al. Characteristics of the early phase of chronicity in acute hepatitis B infection. J Med Virol 1999; 57:331-336.
49. Kobayashi M, Suzuki F, Arase Y, et al. Infection with hepatitis B virus genotype A in Tokyo, Japan during 1976 through 2001. J Gastroenterol 2004; 39:844-850.
50. Chu CJ, Hussain M, Lok AS. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology 2002; 122:1756-1762.
51. Kao JH, Chen DS. HBV genotypes: epidemiology and implications regarding natural history. Current Hepatitis Reports 2006; 5:5-13.
52. Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B virus genotypes and spontaneous hepatitis B e antigen seroconversion in Taiwanese hepatitis B carriers. J Med Virol 2004; 72:363-369.
53. Yuen MF, Fung SK, Tanaka Y, et al. Longitudinal study of hepatitis activity and viral replication before and after HBeAg seroconversion in chronic hepatitis B patients infected with genotypes B and C. J Clin Microbiol 2004; 42:5036-5040.
54. Watanabe K, Takahashi T, Takahashi S, et al. Comparative study of genotype B and C hepatitis B virus-induced chronic hepatitis in relation to the basic core promoter and precore mutations. J Gastroenterol Hepatol 2005; 20:441-449.
55. Chan HL, Wong ML, Hui AY, et al. Hepatitis B virus genotype C takes a more aggressive disease course than hepatitis B virus genotype B in hepatitis B e antigenpositive patients. J Clin Microbiol 2003; 41:1277-1279.
56. Kao JH, Chen PJ, Lai MY, et al. Genotypes and clinical phenotypes of hepatitis B virus in patients with chronic hepatitis B virus infection. J Clin Microbiol 2002; 40:1207-1209.
57. Sumi H, Yokosuka O, Seki N, et al. Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. Hepatology 2003; 37:19-26.
58. Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000; 118:554-559.
59. Kao JH, Chen PJ, Lai MY, Chen DS. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology 2003; 124:327-334.
60. Yuen MF, Tanaka Y, Mizokami M, et al. Role of hepatitis B virus genotypes Ba and C, core promoter and precore mutations on hepatocellular carcinoma: a case control study. Carcinogenesis 2004; 25:1593-1598. (Pubitemid 39214301)
61. Chan HL, Hui AY, Wong ML, et al. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut 2004; 53:1494-1498.
62. Yu MW, Yeh SH, Chen PJ, et al. Genotype and DNA levels of hepatitis B virus and the risk of hepatocellular carcinoma. J Natl Cancer Inst 2005; 97:265-272.
63. Liu CJ, Kao JH. Genetic variability of hepatitis B virus and response to antiviral therapy. Antivir Ther 2008; 13:613-624.
64. Ni YH, Chang MH, Wang KJ, et al. Clinical relevance of hepatitis B virus genotype in children with chronic infection and hepatocellular carcinoma. Gastroenterology 2004; 127:1733-1738.
65. Sanchez-Tapias JM, Costa J, Mas A, et al. Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. Gastroenterology 2002; 123:1848-1856.
66. Kidd-Ljunggren K, Myhre E, Blackberg J. Clinical and serological variation between patients infected with different hepatitis B virus genotypes. J Clin Microbiol 2004; 42:5837-5841.
67. Thakur V, Guptan RC, Kazim SN, et al. Profile, spectrum and significance of HBV genotypes in chronic liver disease patients in the Indian subcontinent. J Gastroenterol Hepatol 2002; 17:165-17
68. Yuen MF, Wong DK, Sablon E, et al. HBsAg seroclearance n chronic hepatitis B in the Chinese: virological, histological, and clinical aspects. Hepatology 2004; 39:1694-1701.
69. Palumbo E, Hepatitis B. Genotypes and response to antiviral therapy: a review. Am J Ther 2007; 14:306-309.
70. Kao JH, Wu NH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes and the response to interferon therapy. J Hepatol 2000; 33:998-1002.
71. Wai CT, Chu CJ, Hussain M, et al. HBV genotype B is associated with better response to interferon therapy in HBeAg (+) chronic hepatitis than genotype C. Hepatology 2002; 36:1425-1430.
72. Liu CJ, Lai MY, Chao YC, et al. Interferon α-2b with and without ribavirin in the treatment of hepatitis B e antigen-positive chronic hepatitis B: a randomized study. Hepatology 2006; 43:742-749.
73. Enomoto M, Tamori A, Nishiguchi S. Hepatitis B virus genotypes and response to antiviral therapy. Clin Lab 2006; 52:43-47.
74. Tseng TC, Kao JH. HBV genotype and clinical outcome of chronic hepatitis B: facts and puzzles. Gastroenterology 2008; 134:1272-1273.
75. Seo Y, Yoon S, Hamano K, et al. Early response to interferon alfa treatment and long-term clinical outcome in Japanese patients with chronic HBV genotype C infection. Int J Mol Med 2004; 13:75-79.
76. Hou J, Schilling R, Janssen HL. Molecular characteristics of hepatitis B virus genotype A confer a higher response to interferon treatment. J Hepatol 2001; 34 Suppl 1:15-16.
77. Erhardt A, Blondin D, Hauck K, et al. Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut 2005; 54:1009-1013.
78. Cooksley WG, Piratvisuth T, Lee SD, et al. Peginterferon alfa-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003; 10:298-305.
79. Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine or HBeAg-positive chronic hepatitis B: a randomized trial. Lancet 2005; 365:123-129.
80. Cooksley G, Manns M, Lau GKK, et al. Effect of genotype and other baseline factors on response to peginterferon alfa-2a (40KD) (Pegasys) in HBeAg-positive chronic hepatitis B: results from a large, randomized study. J Hepatol 2005; 42 Suppl 2:30-31.
81. Flink HJ, Zonneveld M, Hansen BE, et al. Treatment with peg-interferon alfa-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol 2006; 101:297-303.
82. Hadziyannis S, Lau GKK, Marcellin P, et al. Sustained HBsAg seroconversion in patients with chronic hepatitis B treated with peginterferon alfa-2a (40 kDa) (Pegasys). J Hepatol 2005; 42 Suppl 2:178.
83. Kao JH, Liu CJ, Chen DS. Hepatitis B viral genotypes and lamivudine resistance. J Hepatol 2002; 36:303-304.
84. Yuen MF, Wong DK, Sablon E, et al. Hepatitis B virus genotypes B and C do not affect the antiviral response to lamivudine. Antivir Ther 2003; 8:531-534.
85. Chan HL, Wong ML, Hui AY, et al. Hepatitis B virus genotype has no impact on hepatitis B e antigen seroconversion after lamivudine treatment. World J Gastroenterol 2003; 9:2695-2697.
86. Buti M, Cotrina M, Valdes A, et al. Is hepatitis B virus subtype testing useful in predicting virological response and resistance to lamivudine? J Hepatol 2002; 36:445-446.
87. Chien RN, Yeh CT, Tsai SL, et al. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology 2003; 38:1267-1273.
88. Westland C, Delaney W, Yang H, et al. Hepatitis B virus genotypes and virological response in 694 patients in Phase III studies of adefovir dipivoxil. Gastroenterology 2003; 125:107-116.
89. Lurie Y, Manns MP, Gish RG, et al. The efficacy of entecavir is similar regardless of disease-related baseline subgroups in treatment of nucleoside-naive, HBeAg (+) and HBeAg (-) patients with chronic hepatitis B. J Hepatol 2005; 42 Suppl 2:184.
90. Zeng MD, Lu LG, Mao YM, et al. Prediction of significant fibrosis in HBeAg-positive patients with chronic hepatitis B by a noninvasive model. Hepatology 2005; 42:1437-1445.
91. Mohamadnejad M, Montazeri G, Fazlollahi A, et al. Noninvasive markers of liver fibrosis and inflammation in chronic hepatitis B-virus related liver disease. Am J Gastroenterol 2006; 101:2537-2545.
92. Myers RP, Tainturier MH, Ratziu V, et al. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol 2003; 39:222-230. (Pubitemid 36920558)
93. Halfon P, Munteanu M, Poynard T. FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Gastroenterol Clin Biol 2008; 32:22-39.
94. Ngo Y, Benhamou Y, Thibault V, et al. An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load. PLoS ONE 2008; 3:e2573.
95. Poynard T, Zoulim F, Ratziu V, et al. Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection. Am J Gastroenterol 2005; 100:1970-1980.
96. Gerlich WH, Uy A, Lambrecht F, Thomssen R. Cutoff levels of immunoglobulin M antibody against viral core antigen for differentiation of acute, chronic, and past hepatitis B virus infections. J Clin Microbiol 1986; 24:288-293.
97. Brunetto MR, Cerenzia MT, Oliveri F, et al. Monitoring the natural course and response to therapy of chronic hepatitis B with an automated semi-quantitative assay for IgM anti-HBc. J Hepatol 1993; 19:431-436.
98. Colloredo G, Bellati G, Leandro G, et al. Quantitative analysis of IgM anti-HBc in chronic hepatitis B patients using a new 'gray-zone' for the evaluation of 'borderline' values. J Hepatol 1996; 25:644-648.
99. Gerlich WH, Glebe D, Schuttler CG. Deficiencies in the standardization and sensitivity of diagnostic tests for hepatitis B virus. J Viral Hepat 2007; 14:16-21.
100. Theise ND. Liver biopsy assessment in chronic viral hepatitis: a personal, practical approach. Mod Pathol 2007; 20 Suppl 1:S3-S14.
101. Ramalho F, Brunetto MR, Rocca G, et al. Serum markers of hepatitis B virus replication, liver histology and intrahepatic expression of hepatitis B core antigen. J Hepatol 1988; 7:14-20.
102. Volz T, Lutgehetmann M, Wachtler P, et al. Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients. Gastroenterology 2007; 133:843-852.
103. Wang H-C, Wu H-C, Chen C-F, Fausto N, Lei H-Y, Su I-J. Different types of ground glass hepatocytes in chronic hepatitis B virus infection contain specific pre-S mutants that may induce endoplasmic reticulum stress. Am J Pathol 2003; 163:2441-2449.
104. Negro F, Berninger M, Chiaberge E, et al. Detection of HBV DNA by in-situ hybridization using a biotin-labeled probe. J Med Virol 1985; 15:373-382.
105. Nguyen T, Desmond P, Locarnini S. The role of quantitative Hepatitis B serology in the natural history and management of Chronic Hepatitis B. Hepatology International 2009; 3 Suppl 1:S5-S15.
106. Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B virus infection. J Hepatol 2007; 46:160-170.